首页> 美国卫生研究院文献>Case Reports in Immunology >Deficiency of Interleukin-1 Receptor Antagonist: A Case with Late Onset Severe Inflammatory Arthritis Nail Psoriasis with Onychomycosis and Well Responsive to Adalimumab Therapy
【2h】

Deficiency of Interleukin-1 Receptor Antagonist: A Case with Late Onset Severe Inflammatory Arthritis Nail Psoriasis with Onychomycosis and Well Responsive to Adalimumab Therapy

机译:白细胞介素-1受体拮抗剂的不足:迟发性重度炎性关节炎指甲癣合并甲癣对阿达木单抗治疗反应良好的病例

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

DIRA (deficiency of the IL-1Ra) is a rare condition that usually presents in the neonatal period. Patients with DIRA present with systemic inflammation, respiratory distress, joint swelling, pustular rash, multifocal osteomyelitis, and periostitis. Previously, we reported a patient with a novel mutation in IL1RN with a healthy neonatal period, a late-onset of pustular dermatosis, inflammatory arthritis, and excellent response to canakinumab treatment. Herein, we are presenting a new case of late-onset DIRA syndrome, carrying a different mutation and showing different clinical findings. This patient is the first one in the literature with the inflammatory arthritis, nail psoriasis, and onychomycosis and with her remarkable response to monoclonal antibodies. The case responded well and fully recovered after treatment with adalimumab, but not with canakinumab. The DIRA disease can lead to death from multiple organ failures and if recognized early, the treatment with replacement of the deficient protein with biologic agents induces rapid and complete remission. Therefore, clinical symptoms should be learned exactly by the pediatricians, pediatric rheumatologists, and immunologists; and molecular analysis targeting this defect must be performed as early as possible.
机译:DIRA(IL-1Ra缺乏症)是一种罕见的疾病,通常出现在新生儿期。 DIRA患者出现全身性炎症,呼吸窘迫,关节肿胀,脓疱疹,多灶性骨髓炎和骨膜炎。以前,我们报道了一名患有IL1RN新型突变,具有健康新生儿期,脓疱性皮肤病晚发,炎性关节炎以及对canakinumab治疗的出色反应的患者。在这里,我们提出了一种新的晚期DIRA综合征病例,其携带不同的突变并显示出不同的临床发现。该患者是炎症性关节炎,指甲银屑病和灰指甲的第一例文献报道,对单克隆抗体反应显着。该病例反应良好,并用阿达木单抗治疗后完全康复,但未使用卡那基单抗治疗。 DIRA疾病可导致多器官功能衰竭导致死亡,如果能及早发现,用生物制剂替代缺陷蛋白的治疗可导致快速完全缓解。因此,儿科医师,儿科风湿病学家和免疫学家应准确了解临床症状。针对这种缺陷的分子分析必须尽早进行。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号